Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
S&P Global Inc.: Mega IPOs Such as SpaceX Won't Be Quickly Added to S&P 500 Index

S&P Global Inc.: Mega IPOs Such as SpaceX Won't Be Quickly Added to S&P 500 Index

BlockBeatsBlockBeats2026/06/05 04:30

BlockBeats News, June 5th, Standard Poor's Global announced that it will maintain its existing eligibility criteria for major benchmark indices such as the SP 500 Index, rejecting a proposal to expedite the rapid inclusion of giant companies like SpaceX after their IPO. On Thursday, the SP Index stated in a press release that it will not shorten the current 12-month "seasoning period" for newly listed companies, nor will it waive the existing profitability and public float requirements based on company size.


This means that SpaceX will need to wait at least one year after its IPO to be included in the SP 500 Index, and it will need to meet the index's existing profitability and public float requirements. This includes the company having achieved profitability in the most recent quarter as well as the sum of the past four quarters according to GAAP, and having a public float of no less than 50%. (Jinse)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage